Teva acquired Emalex Biosciences, an American company specializing in neurological diseases, for up to $900 million on April 26, 2023. The deal includes a $700 million upfront payment and contingent milestone payments of up to $200 million based on regulatory approvals.
Deal structure and financing
The acquisition is financed with a combination of cash and debt issuance by Teva. Specific equity or debt splits have not been disclosed, but the company's current financial position allows it to pursue strategic acquisitions without taking significant additional leverage risk. As of the announcement date, Teva held approximately $3.7 billion in cash against total debt of around $16 billion. The financing was arranged with major investment banks involved in previous large-scale pharmaceutical transactions; however, exact details remain undisclosed.
Strategic context
Teva's acquisition of Emalex reflects its renewed focus on innovative drugs following a period marked by financial challenges and strategic missteps. Historically known for acquiring companies developing promising drug candidates at late-stage clinical trials, the deal underscores Teva’s shift towards biotech and specialty pharmaceuticals. Emalex Biosciences’ pipeline features an orphan drug targeting Tourette syndrome in children, aligning with Teva's expertise in neurological diseases.
Regulatory path
The acquisition has been reviewed by regulatory authorities in Israel and the United States. Due to the nature of the transaction involving a U.S.-based target and potential cross-border revenue streams, Teva would have had to file under both HSR Act requirements in the US and relevant Israeli merger control rules. Given the deal’s size and industry significance, it is likely that antitrust concerns were minimal, with no specific remedies required. The process has been relatively swift, reflecting regulatory approval without significant hurdles.